Coherus Oncology, Inc. (NASDAQ:CHRS) Receives $5.51 Consensus Target Price from Brokerages

Shares of Coherus Oncology, Inc. (NASDAQ: CHRS - Get Free Report) have received an average rating of "Hold" from the five ratings firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating